

SUPPLEMENTARY DATA

Table S1. Multivariable Cox regression model for the composite endpoint of all-cause mortality or heart failure rehospitalization at 1 year

Variable	HR	95%CI	P	
<i>Baseline covariates</i>				
Age at admission, y	1.026	1.010-1.043	.002	
Sex, male	0.871	0.696-1.091	.229	
Heart rate at admission, bpm	1.006	1.001-1.011	.024	
Hemoglobin at admission, g/dL	1.027	0.979-1.078	.269	
NYHA baseline functional class	1.714	1.431-2.053	< .001	
Systolic BP at admission, mmHg	0.998	0.993-1.002	.379	
Pleural effusion at admission	1.165	0.938-1.448	.167	
Furosemide doce	1.479	1.171-1.867	.001	
Creatinine at admission, mg/dL	1.210	1.033-1.417	.018	
Sodium at admission, mEq/L	0.994	0.976-1.013	.533	
Ln(BNP)	1.226	1.083-1.387	.001	
<i>SGLT2 inhibitor use at discharge (ref: no SGLT2i, ECS 0)</i>				
SGLT2i (ECS 0)	1.208	0.730-1.998	.462	
<i>Extravascular congestion score — ECS (ref: ECS 0)</i>				
ECS 1	1.723	1.043-2.847	.034	
ECS 2–3	2.391	1.289-4.436	.006	
<i>Effect of SGLT2i by ECS category (linear combination) — P for interaction = .029</i>				
SGLT2i in ECS 0	1.208	0.730-1.998	.462	
SGLT2i in ECS 1	0.762	0.570-1.017	.065	
SGLT2i in ECS 2-3	0.456	0.272-0.765	.003	

BP, blood pressure; BNP, B-type natriuretic peptide; CI, confidence interval; ECS, extravascular congestion score (range 0-3, categories 2 and 3 merged); HR, hazard ratio; NYHA, New York Heart Association; SGLT2i, sodium-glucose cotransporter 2 inhibitor.

Table S2. Baseline characteristics according to SGLT2i treatment at discharge

Variable	Total (N = 821)	No SGLT2i (n = 202)	SGLT2i (n = 619)	P
Demographic parameters and medical history				
Age, y	88 [83-91]	88 [84-91]	87 [83-91]	.295
Female sex	548 (66.8)	133 (65.8)	415 (67)	.753
Hypertension	743 (90.5)	174 (86.1)	569 (91.9)	.015
Diabetes mellitus	309 (37.6)	64 (31.7)	245 (39.6)	.044
COPD	225 (27.4)	55 (27.2)	170 (27.5)	.948
Atrial fibrillation	514 (62.6)	135 (66.8)	379 (61.2)	.153
Ischemic heart disease	158 (19.2)	33 (16.3)	125 (20.2)	.227
Valvular disease	175 (21.3)	41 (20.3)	134 (21.7)	.684
Neoplasia	65 (7.9)	11 (5.5)	54 (8.7)	.134
Length of stay, d	5 [4-8]	6.5 [4-10]	5 [3-8]	< .001
Physical examination				
NYHA class				.700
Class I	60 (7.3)	12 (5.9)	48 (7.8)	
Class II	530 (64.6)	128 (63.4)	402 (65)	
Class III	221 (26.9)	59 (29.2)	162 (26.2)	
Class IV	10 (1.2)	3 (1.5)	7 (1.1)	
Systolic BP, mmHg	132 [116-150]	133 [117-150]	132 [115-150]	.876
Diastolic BP, mmHg	72 [63-83]	72 [61-82]	72 [64-83]	.302
Heart rate, bpm	80 [70-93]	80 [69-93]	80 [70-93]	.861
Peripheral edema at admission	549 (66.9)	141 (69.8)	408 (65.9)	.308
Peripheral edema at discharge	99 (12.1)	23 (11.4)	76 (12.3)	.735
Echocardiography				
LVEF, %	60.2 [52.8-67.6]	61.6 [55-68]	60 [52-67.4]	.128
LVEF $\geq$ 50*	588 (79.0)	140 (82.8)	448 (77.9)	.167
TAPSE, cm	2.0 [1.8-2.3]	2 [1.7-2.4]	2 [1.8-2.3]	.664
sPAP, mmHg*	49.8 [40.0-59.4]	47.8 [40-60]	50 [40-59.4]	.755
Point-of-care ultrasound				
Dilated IVC*	416 (60.2)	70 (59.3)	346 (60.4)	.830
Pleural effusion at admission	273 (33.3)	70 (34.7)	203 (32.8)	.626
Pleural effusion at discharge	160 (27.0)	13 (15.3)	147 (28.9)	.007
Laboratory tests				
Creatinine, mg/dL	1.2 [0.9-1.6]	1.3 [0.9-1.7]	1.2 [0.9-1.6]	.085
eGFR, mL/min/1.73 m ²	47.3 [33.3-64.1]	45.6 [30-62.6]	48.4 [34.1-64.7]	.065
Urea, g/dL	61 [44-87]	66 [46-100]	59 [43-85]	.031
Sodium, mEq/L	139 [135-141]	138 [135-141]	139 [136-141]	.888
Potassium, mEq/L	4.4 [4.1-4.9]	4.5 [4.1-4.9]	4.4 [4.1-4.9]	.396
Chloride, mEq/L	103 [99-106]	102 [98-106]	103 [99-106]	.151
Hemoglobin, g/dL	12.0 [10.5-13.4]	11.9 [10.3-13.2]	12 [10.6-13.5]	.056
Leukocytes, $\times 10^3/\mu\text{L}$	8.44 [6.59-10.9]	8.68 [6.48-11.8]	8.4 [6.62-10.7]	.294
BNP, pg/mL	590 [320-1079]	509 [305-1012]	616 [335-1109]	.086
CA125, U/mL	55.6 [29.5-106.1]	55.6 [31.4-99.2]	55.6 [27.9-112.9]	.849
Treatment at discharge				
ACEi/ARB/sacubitril-valsartan	478 (58.2)	99 (49)	379 (61.2)	.002
Beta-blockers	456 (55.5)	107 (53)	349 (56.4)	.397

<i>MRA</i>	105 (12.8)	26 (12.9)	79 (12.8)	.968
<i>Oral furosemide dose, mg/d</i>	60 [40-80]	80 [40-80]	60 [40-80]	.346
Clinical events at 1 year				
<i>All-cause mortality</i>	315 (38.7)	100 (49.8)	215 (35.1)	< .001
<i>HF rehospitalization</i>	261 (32.0)	72 (35.6)	189 (30.8)	.214
<i>Combined endpoint</i>	436 (53.5)	129 (63.9)	307 (50.1)	.001

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; BP, blood pressure; bpm, beats per minute; CA125, carbohydrate antigen 125; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HF, heart failure; IVC, inferior vena cava; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; SGLT2i, sodium-glucose cotransporter 2 inhibitor; sPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion.

The data are presented as No. (%) or median [interquartile range].